Caliway Biopharmaceuticals Co Ltd AI Stock Analysis
Caliway Biopharmaceuticals Co Ltd (6919) AI Stock Analysis
Caliway Biopharmaceuticals Co Ltd
(TWSE:6919)
The score is dominated by weak financial performance: negligible revenue, large operating losses, and persistent cash burn that exceeds the remaining asset base, making additional external funding and shareholder dilution likely. Technicals reinforce the caution, with the price below all key moving averages and negative MACD momentum, though oversold RSI and Stochastic readings hint at possible short-term stabilisation. Valuation provides no cushion given negative earnings and no dividend. The main positives — a debt-free balance sheet, a 40% narrower net loss, and improved gross margin — are not yet enough to offset the high-risk, pre-commercial profile. Note: the computed weighted result falls below the platform minimum, so the reported score reflects the floor of the scoring range.
Caliway Biopharmaceuticals Co Ltd (6919) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 107.38B
- Dividend Yield
- ―
- Average Volume (3M)
- 7.20M
- Price to Earnings (P/E)
- -174.9
- Beta (1Y)
- 0.64
- Revenue Growth
- -54.34%
- EPS Growth
- -24.43%
- Country
- TW
- Employees
- 20
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Caliway Biopharmaceuticals Co Ltd Business Overview & Revenue Model
Company Description
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phas...
Caliway Biopharmaceuticals Co Ltd Financial Statement Overview
Summary
Caliway shows the classic development-stage biotech profile: minimal revenue (about NT$38 million, down 14%), an operating loss of NT$706 million, and negative free cash flow of NT$443 million. The income statement (21) and cash flow (18) are the weakest links, with burn escalating from roughly NT$47 million in 2020 to over NT$500 million recently. The balance sheet (42) is better, supported by an essentially debt-free capital structure, but reported equity and total assets collapsed to roughly NT$300 million — less than one year of cash burn — implying limited runway and a likely dilutive equity raise. Partial offsets include a 40% narrowing of the net loss and a gross margin rebound to about 70%.
Income Statement
21NegativeBalance Sheet
42NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.36M | 37.98M | 44.36M | 38.88M | 12.83M | 12.32M |
| Gross Profit | -10.40M | 26.48M | 1.25M | 27.44M | -15.74M | 9.22M |
| EBITDA | -799.61M | -675.43M | -686.45M | -484.97M | -294.49M | -207.15M |
| Net Income | -257.93M | -351.35M | -587.85M | -487.85M | -286.33M | -224.00M |
Balance Sheet | ||||||
| Total Assets | 9.43B | 301.89M | 9.77B | 3.83B | 1.23B | 711.96M |
| Cash, Cash Equivalents and Short-Term Investments | 4.05B | 154.87M | 9.67B | 3.71B | 1.11B | 594.12M |
| Total Debt | 107.95M | 95.53K | 11.87M | 20.46M | 28.68M | 36.73M |
| Total Liabilities | 223.88M | 2.03M | 73.69M | 85.55M | 68.82M | 68.15M |
| Stockholders Equity | 9.21B | 299.86M | 9.70B | 3.74B | 1.16B | 643.81M |
Cash Flow | ||||||
| Free Cash Flow | -300.88M | -443.04M | -533.40M | -433.62M | -256.93M | -125.43M |
| Operating Cash Flow | -280.99M | -425.90M | -522.31M | -423.94M | -242.76M | -110.55M |
| Investing Cash Flow | -4.17B | -5.62B | -2.49B | 157.09M | -470.54M | -14.88M |
| Financing Cash Flow | -107.83M | -119.11M | 6.49B | 3.03B | 771.72M | 625.98M |
Caliway Biopharmaceuticals Co Ltd Peers Comparison
Overall Rating
TW:647260Neutral
TW:179557Neutral
TW:694933Underperform- TW:691930Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6472 | 60Neutral | TWD 50.12B | 32.71 | ― | 2.48% | -5.57% | -62.77% |
| TW:1795 | 57Neutral | TWD 44.28B | 10.79 | ― | 1.64% | 48.98% | -21.95% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6949 | 33Underperform | TWD 54.47B | -138.20 | ― | ― | 7.81% | ― |
| TW:6919 | 30Underperform | TWD 109.78B | -174.87 | ― | ― | -54.34% | -24.43% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6919 | Caliway Biopharmaceuticals Co Ltd | 70.00 | -57.00 | -44.88% | |
| TW:1795 | Lotus Pharmaceutical Co., Ltd. | 156.00 | -123.55 | -44.20% | |
| TW:6472 | Bora Pharmaceuticals Co Ltd | 403.00 | -209.62 | -34.22% | |
| TW:6696 | Lin BioScience, Inc. | 166.50 | 138.55 | 495.71% | |
| TW:6949 | PELL Bio-Med Technology Co Ltd | 44.75 | 25.91 | 137.55% | |
| TW:7924 | TLC BioSciences Corp | 402.50 | 192.00 | 91.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026